Rocket Pharmaceuticals, INC Form 4 insider transactions

Rocket Pharmaceuticals' VP of Finance, John Militello, was granted 40,000 Restricted Stock Units, increasing his direct beneficial ownership to 95,924 shares.

Rocket Pharmaceuticals' General Counsel, Martin Wilson, was granted 150,000 Restricted Stock Units, aligning executive incentives with shareholder value.

Rocket Pharmaceuticals' Chief Medical & Gene Therapy Officer, Jonathan David Schwartz, was granted 80,000 Restricted Stock Units.

Elisabeth Bjork, a Director at Rocket Pharmaceuticals, Inc., purchased 10,000 shares of common stock for $3.41 per share.

A Rocket Pharmaceuticals officer sold common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Rocket Pharmaceuticals' Chief Medical Officer, Jonathan David Schwartz, sold shares of common stock to cover tax obligations related to RSU vesting.

Rocket Pharmaceuticals General Counsel Martin Wilson sold shares to cover tax obligations related to RSU vesting.

Rocket Pharmaceuticals CEO Gaurav Shah reported a disposition of 2,234 common shares for tax withholding related to Restricted Stock Unit vesting.

A Rocket Pharmaceuticals officer sold 11,161 shares of common stock to cover tax withholding obligations related to RSU vesting.

A Rocket Pharmaceuticals executive sold 7,043 shares of common stock to cover tax withholding obligations related to RSU vesting.

Rocket Pharmaceuticals General Counsel Martin Wilson sold 12,109 shares of common stock to cover tax withholding obligations related to RSU vesting.

Rocket Pharmaceuticals' Chief Operating Officer, Christopher James Stevens, received substantial equity grants comprising Restricted Stock Units and stock options.

Rocket Pharmaceuticals, Inc. Director Piratip Pratumsuwan was granted 30,000 restricted stock units, which will vest in full on June 18, 2026.

Pedro P. Granadillo, a Director at Rocket Pharmaceuticals, Inc., was granted 54,734 restricted stock units, including units in lieu of director fees, vesting in June 2026.

Mikael Dolsten, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 restricted stock units (RSUs) on June 18, 2025, which will vest in full on June 18, 2026.

Rocket Pharmaceuticals, Inc. Director Gotham Makker was granted a total of 49,434 restricted stock units (RSUs) on June 18, 2025, which are set to vest in full on June 18, 2026.

Roderick Wong, a Director and 10% owner of Rocket Pharmaceuticals, Inc., was granted 47,667 restricted stock units (RSUs) on June 18, 2025, including units in lieu of director fees, which are set to vest on June 18, 2026.

Rocket Pharmaceuticals, Inc. Director Fady Ibraham Malik is scheduled to acquire 30,000 restricted stock units, which will vest in full on June 18, 2026.

Carsten Boess, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 restricted stock units, aligning his interests with shareholders.

Elisabeth Bjork, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 Restricted Stock Units (RSUs) as part of her compensation.

Director David Southwell acquired 30,000 shares of Rocket Pharmaceuticals common stock on June 18, 2025, through the grant of restricted stock units.

Rocket Pharmaceuticals' Chief Financial Officer, Aaron Ondrey, sold 1,477 shares of common stock on July 3, 2025, at $2.882 per share to cover tax withholding obligations related to RSU vesting.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold 357 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 801 shares of common stock at $6.446 per share to cover tax withholding obligations related to vesting Restricted Stock Units.

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold shares to cover tax obligations related to vesting Restricted Stock Units.

Gaurav Shah, CEO of Rocket Pharmaceuticals, sold 2,253 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 587 shares of common stock on May 20, 2025, at a price of $6.446 per share to cover tax withholding obligations related to vesting Restricted Stock Units.

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 1,582 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 946 shares of common stock on May 16, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold 655 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.